Nuuron secures million-euro investment for the development of a digital Alzheimer's drug

Nuuron's digital memory pacemaker promises to improve memory function in Alzheimer's patients - investors such as HTGF and RoX Health are enthusiastic.

Berlin, October 31, 2024 - Nuuron is developing a fully digital therapy for the treatment of Alzheimer's disease. The Berlin-based neurotech startup uses its proprietary neuromodulation technology to activate the memory center of Alzheimer's patients with high-frequency, digital-photonic stimuli. These digital stimuli are designed to improve the storage and retrieval of information. Nuuron uses the retina as an interface between the computer and the brain and integrates state-of-the-art virtual and augmented reality technologies into the therapy.

HTGF leads oversubscribed seed round

Nuuron has raised more than 3.5 million euros in an oversubscribed seed round. In addition to High-Tech Gründerfonds (HTGF), IBB Ventures, the Business Angel Club Berlin and other private investors are also among the backers. There is also a strategic partnership with RoX Health, a subsidiary of the international healthcare company Roche.

Nuuron's approach represents a breakthrough in the treatment of Alzheimer's dementia. The groundbreaking eye stimulation addresses an unprecedented therapeutic target.

Tilmann Petersen, Investment Manager at HTGF

Nuuron will use the investment to conduct preclinical animal studies in collaboration with the German Center for Neurodegenerative Diseases (DZNE) and clinical studies at the Charité. In addition to product development, the company is preparing for market entry in Europe and the USA to make its therapy available worldwide.

Our scientists have deciphered the neuronal code of the memory center and used it to develop a digital drug for the treatment of Alzheimer's dementia. We call it the Memory Pacemaker - an effective therapy that will be prescribed to doctors and reimbursed by health insurance companies

Dr. Markus Müschenich, co-founder of Nuuron

A new treatment option for millions of Alzheimer's patients worldwide

"We have accompanied Nuuron in a strategic collaboration from the very beginning. The innovative approach shows the potential of digital therapeutics and how we can treat complex diseases even more effectively in the future," explains Dr. Robert Schnitzler, CEO of RoX Health.

There are currently over 55 million people worldwide living with Alzheimer's or similar forms of dementia. This number is predicted to rise to 139 million by 2050. The market for Alzheimer's therapies, which amounted to USD 5.8 billion in 2023, could grow to USD 11.4 billion by 2032. Nuuron was founded in 2024 by Fabian Queisner and Dr. Markus Müschenich. The Scientific Director is Priv.-Doz. Dr. Julian Keil. The Nuuron team consists of experts in the fields of neuroscience, medicine, neuroinformatics, machine learning and public health.